UroGen Pharma Ltd.
URGN
$24.38
-$4.08-14.34%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.04% | 10.83% | 7.84% | 4.40% | 20.87% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.04% | 10.83% | 7.84% | 4.40% | 20.87% |
| Cost of Revenue | 33.63% | 59.26% | 34.84% | 8.09% | 3.63% |
| Gross Profit | 6.39% | 5.33% | 5.11% | 4.00% | 23.08% |
| SG&A Expenses | 29.86% | 43.73% | 28.09% | 37.50% | 33.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.35% | 37.70% | 28.41% | 34.04% | 24.44% |
| Operating Income | -56.09% | -60.41% | -43.41% | -81.79% | -29.96% |
| Income Before Tax | -45.88% | -46.64% | -34.81% | -57.31% | -7.74% |
| Income Tax Expenses | -1,258.24% | 2,571.05% | 625.93% | -31.27% | 1,111.11% |
| Earnings from Continuing Operations | -40.87% | -49.51% | -35.80% | -44.19% | -8.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.87% | -49.51% | -35.80% | -44.19% | -8.20% |
| EBIT | -56.09% | -60.41% | -43.41% | -81.79% | -29.96% |
| EBITDA | -51.08% | -60.53% | -43.82% | -83.72% | -31.27% |
| EPS Basic | -37.11% | -26.85% | -6.12% | -10.84% | 25.29% |
| Normalized Basic EPS | -41.99% | -24.39% | -5.35% | -17.12% | 25.61% |
| EPS Diluted | -37.11% | -26.85% | -6.12% | -10.84% | 25.29% |
| Normalized Diluted EPS | -41.99% | -24.39% | -5.35% | -17.12% | 25.61% |
| Average Basic Shares Outstanding | 2.73% | 17.87% | 27.96% | 30.09% | 44.84% |
| Average Diluted Shares Outstanding | 2.73% | 17.87% | 27.96% | 30.09% | 44.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |